SAN DIEGO–(BUSINESS WIRE)– #biomanufacturing–National Resilience, Inc. (Resilience), a technology-driven biomanufacturing leader dedicated to broadening access to complex medicines, today announced the expansion of its collaboration with Parvus Therapeutics (“Parvus”) to support the development and manufacturing their second novel autoimmune drug candidate, PVT401, targeting Inflammatory Bowel Disease (IBD). This announcement follows the successful development and manufacturing of the Parvus clinical-stage drug